PURPOSE: To understand the changes in gene expression in polycythemia vera (PV) progenitor cells and their relationship to JAK2V617F. EXPERIMENTAL DESIGN: Messenger RNA isolated from CD34(+) cells from nine PV patients and normal controls was profiled using Affymetrix arrays. Gene expression change mediated by JAK2V617F was determined by profiling CD34(+) cells transduced with the kinase and by analysis of leukemia cell lines harboring JAK2V617F, treated with an inhibitor. RESULTS: A PV expression signature was enriched for genes involved in hematopoietic development, inflammatory responses, and cell proliferation. By quantitative reverse transcription-PCR, 23 genes were consistently deregulated in all patient samples. Several of these genes such as WT1 and KLF4 were regulated by JAK2, whereas others such as NFIB and EVI1 seemed to be deregulated in PV by a JAK2-independent mechanism. Using cell line models and comparing gene expression profiles of cell lines and PV CD34(+) PV specimens, we have identified panels of 14 JAK2-dependent genes and 12 JAK2-independent genes. These two 14- and 12-gene sets could separate not only PV from normal CD34(+) specimens, but also other MPN such as essential thrombocytosis and primary myelofibrosis from their normal counterparts. CONCLUSIONS: A subset of the aberrant gene expression in PV progenitor cells can be attributed to the action of the mutant kinase, but there remain a significant number of genes characteristic of the disease but deregulated by as yet unknown mechanisms. Genes deregulated in PV as a result of the action of JAK2V617F or independent of the kinase may represent other targets for therapy.
PURPOSE: To understand the changes in gene expression in polycythemia vera (PV) progenitor cells and their relationship to JAK2V617F. EXPERIMENTAL DESIGN: Messenger RNA isolated from CD34(+) cells from nine PV patients and normal controls was profiled using Affymetrix arrays. Gene expression change mediated by JAK2V617F was determined by profiling CD34(+) cells transduced with the kinase and by analysis of leukemia cell lines harboring JAK2V617F, treated with an inhibitor. RESULTS: A PV expression signature was enriched for genes involved in hematopoietic development, inflammatory responses, and cell proliferation. By quantitative reverse transcription-PCR, 23 genes were consistently deregulated in all patient samples. Several of these genes such as WT1 and KLF4 were regulated by JAK2, whereas others such as NFIB and EVI1 seemed to be deregulated in PV by a JAK2-independent mechanism. Using cell line models and comparing gene expression profiles of cell lines and PV CD34(+) PV specimens, we have identified panels of 14 JAK2-dependent genes and 12 JAK2-independent genes. These two 14- and 12-gene sets could separate not only PV from normal CD34(+) specimens, but also other MPN such as essential thrombocytosis and primary myelofibrosis from their normal counterparts. CONCLUSIONS: A subset of the aberrant gene expression in PV progenitor cells can be attributed to the action of the mutant kinase, but there remain a significant number of genes characteristic of the disease but deregulated by as yet unknown mechanisms. Genes deregulated in PV as a result of the action of JAK2V617F or independent of the kinase may represent other targets for therapy.
Authors: Julia A Alberta; Gregory M Springett; Helen Rayburn; Thomas A Natoli; Janet Loring; Jordan A Kreidberg; David Housman Journal: Blood Date: 2002-12-05 Impact factor: 22.113
Authors: L Catani; R Zini; D Sollazzo; E Ottaviani; A M Vannucchi; S Ferrari; M Baccarani; N Vianelli; R M Lemoli; R Manfredini Journal: Leukemia Date: 2009-01-08 Impact factor: 11.528
Authors: Amy V Jones; Sebastian Kreil; Katerina Zoi; Katherine Waghorn; Claire Curtis; Lingyan Zhang; Joannah Score; Rachel Seear; Andrew J Chase; Francis H Grand; Helen White; Christine Zoi; Dimitris Loukopoulos; Evangelos Terpos; Elisavet-Christine Vervessou; Beate Schultheis; Michael Emig; Thomas Ernst; Eva Lengfelder; Rüdiger Hehlmann; Andreas Hochhaus; David Oscier; Richard T Silver; Andreas Reiter; Nicholas C P Cross Journal: Blood Date: 2005-05-26 Impact factor: 22.113
Authors: A Tefferi; A Pardanani; K-H Lim; O Abdel-Wahab; T L Lasho; J Patel; N Gangat; C M Finke; S Schwager; A Mullally; C-Y Li; C A Hanson; R Mesa; O Bernard; F Delhommeau; W Vainchenker; D G Gilliland; R L Levine Journal: Leukemia Date: 2009-03-05 Impact factor: 11.528
Authors: Norihiko Kawamata; Seishi Ogawa; Go Yamamoto; Soren Lehmann; Ross L Levine; Yana Pikman; Yasuhito Nannya; Masashi Sanada; Carl W Miller; D Gary Gilliland; H Phillip Koeffler Journal: Exp Hematol Date: 2008-08-23 Impact factor: 3.084
Authors: Swarna Mehrotra; Bhumika Sharma; Sonali Joshi; Barbara Kroczynska; Beata Majchrzak; Brady L Stein; Brandon McMahon; Jessica K Altman; Jonathan D Licht; Darren P Baker; Elizabeth A Eklund; Amittha Wickrema; Amit Verma; Eleanor N Fish; Leonidas C Platanias Journal: J Biol Chem Date: 2013-06-28 Impact factor: 5.157
Authors: Baobing Zhao; Yang Mei; Lan Cao; Jingxin Zhang; Ronen Sumagin; Jing Yang; Juehua Gao; Matthew J Schipma; Yanfeng Wang; Chelsea Thorsheim; Liang Zhao; Timothy Stalker; Brady Stein; Qiang Jeremy Wen; John D Crispino; Charles S Abrams; Peng Ji Journal: J Clin Invest Date: 2017-11-20 Impact factor: 14.808
Authors: Brady L Stein; Donna M Williams; Ophelia Rogers; Mary Ann Isaacs; Jerry L Spivak; Alison R Moliterno Journal: Exp Hematol Date: 2010-10-01 Impact factor: 3.084
Authors: Sangeeta Nischal; Sanchari Bhattacharyya; Maximilian Christopeit; Yiting Yu; Li Zhou; Tushar D Bhagat; Davendra Sohal; Britta Will; Yongkai Mo; Masako Suzuki; Animesh Pardanani; Michael McDevitt; Jaroslaw P Maciejewski; Ari M Melnick; John M Greally; Ulrich Steidl; Alison Moliterno; Amit Verma Journal: Cancer Res Date: 2012-10-11 Impact factor: 12.701
Authors: Katrin Faber; Lars Bullinger; Christine Ragu; Angela Garding; Daniel Mertens; Christina Miller; Daniela Martin; Daniel Walcher; Konstanze Döhner; Hartmut Döhner; Rainer Claus; Christoph Plass; Stephen M Sykes; Steven W Lane; Claudia Scholl; Stefan Fröhling Journal: J Clin Invest Date: 2012-12-03 Impact factor: 14.808
Authors: Raajit Rampal; Fatima Al-Shahrour; Omar Abdel-Wahab; Jay P Patel; Jean-Philippe Brunel; Craig H Mermel; Adam J Bass; Jennifer Pretz; Jihae Ahn; Todd Hricik; Outi Kilpivaara; Martha Wadleigh; Lambert Busque; D Gary Gilliland; Todd R Golub; Benjamin L Ebert; Ross L Levine Journal: Blood Date: 2014-04-16 Impact factor: 22.113
Authors: Jerry L Spivak; Michael Considine; Donna M Williams; Conover C Talbot; Ophelia Rogers; Alison R Moliterno; Chunfa Jie; Michael F Ochs Journal: N Engl J Med Date: 2014-08-28 Impact factor: 91.245
Authors: Huichun Zhan; Christopher Cardozo; Wayne Yu; Antai Wang; Alison R Moliterno; Chi V Dang; Jerry L Spivak Journal: Blood Cells Mol Dis Date: 2012-12-21 Impact factor: 3.039
Authors: Edwin Chen; Philip A Beer; Anna L Godfrey; Christina A Ortmann; Juan Li; Ana P Costa-Pereira; Catherine E Ingle; Emmanouil T Dermitzakis; Peter J Campbell; Anthony R Green Journal: Cancer Cell Date: 2010-11-16 Impact factor: 31.743
Authors: K L Rice; X Lin; K Wolniak; B L Ebert; W Berkofsky-Fessler; M Buzzai; Y Sun; C Xi; P Elkin; R Levine; T Golub; D G Gilliland; J D Crispino; J D Licht; W Zhang Journal: Blood Cancer J Date: 2011-11-11 Impact factor: 11.037